Press Release: Bristol Myers Squibb to Report Results for Third Quarter 2025 on October 30, 2025

Dow Jones

Sep 19

PRINCETON, N.J.--(BUSINESS WIRE)--September 19, 2025--

Bristol Myers Squibb $(BMY)$ will announce results for the third quarter of 2025 on Thursday, October 30, 2025. Company executives will review financial results with the investment community during a conference call beginning at 8:00 a.m. ET.

Investors and the general public are invited to listen to a live webcast of the call at http://investor.bms.com. Materials related to the call will be available at http://investor.bms.com prior to the start of the conference call.

A replay of the webcast will be available at http://investor.bms.com approximately three hours after the conference call concludes.

About Bristol Myers Squibb: Transforming Patients' Lives Through Science

At Bristol Myers Squibb, our mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. We are pursuing bold science to define what's possible for the future of medicine and the patients we serve. For more information, visit us at BMS.com and follow us on LinkedIn, X, YouTube, Facebook and Instagram.

corporatefinancial-news

View source version on businesswire.com: https://www.businesswire.com/news/home/20250919662251/en/

 
    CONTACT:    Media Relations:

media@bms.com

Investor Relations:

investor.relations@bms.com

(END) Dow Jones Newswires

September 19, 2025 07:01 ET (11:01 GMT)

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2568874257"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2568874257\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2568874257?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-19 19:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2568874257","market":"fut","top_or_hot":-1,"title":"Press Release: Bristol Myers Squibb to Report Results for Third Quarter 2025 on October 30, 2025","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\nPRINCETON, N.J.--(BUSINESS WIRE)--September 19, 2025-- \n</pre>\n<p>\n     Bristol Myers Squibb <a href=\"https://laohu8.com/S/BMY\">$(BMY)$</a> will announce results for the third quarter of 2025 on Thursday, October 30, 2025. Company executives will review financial results with the investment community during a conference call beginning at 8:00 a.m. ET. \n</p>\n<p>\n     Investors and the general public are invited to listen to a live webcast of the call at http://investor.bms.com. Materials related to the call will be available at http://investor.bms.com prior to the start of the conference call. \n</p>\n<p>\n     A replay of the webcast will be available at http://investor.bms.com approximately three hours after the conference call concludes. \n</p>\n<p>\n     About Bristol Myers Squibb: Transforming Patients' Lives Through Science \n</p>\n<p>\n     At Bristol Myers Squibb, our mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. We are pursuing bold science to define what's possible for the future of medicine and the patients we serve. For more information, visit us at BMS.com and follow us on LinkedIn, X, YouTube, <a href=\"https://laohu8.com/S/META\">Facebook</a> and Instagram. \n</p>\n<p>\n     corporatefinancial-news \n</p>\n<p>\n     View source version on businesswire.com: https://www.businesswire.com/news/home/20250919662251/en/ \n</p>\n<pre style=\"white-space: pre\">\n \n    CONTACT:    Media Relations: \n</pre>\n<p>\n     media@bms.com \n</p>\n<p>\n     Investor Relations: \n</p>\n<p>\n     investor.relations@bms.com \n</p>\n<pre style=\"white-space: pre\">\n \n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  September 19, 2025 07:01 ET (11:01 GMT)\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Press Release: Bristol Myers Squibb to Report Results for Third Quarter 2025 on October 30, 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPress Release: Bristol Myers Squibb to Report Results for Third Quarter 2025 on October 30, 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-09-19 19:01</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\nPRINCETON, N.J.--(BUSINESS WIRE)--September 19, 2025-- \n</pre>\n<p>\n     Bristol Myers Squibb <a href=\"https://laohu8.com/S/BMY\">$(BMY)$</a> will announce results for the third quarter of 2025 on Thursday, October 30, 2025. Company executives will review financial results with the investment community during a conference call beginning at 8:00 a.m. ET. \n</p>\n<p>\n     Investors and the general public are invited to listen to a live webcast of the call at http://investor.bms.com. Materials related to the call will be available at http://investor.bms.com prior to the start of the conference call. \n</p>\n<p>\n     A replay of the webcast will be available at http://investor.bms.com approximately three hours after the conference call concludes. \n</p>\n<p>\n     About Bristol Myers Squibb: Transforming Patients' Lives Through Science \n</p>\n<p>\n     At Bristol Myers Squibb, our mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. We are pursuing bold science to define what's possible for the future of medicine and the patients we serve. For more information, visit us at BMS.com and follow us on LinkedIn, X, YouTube, <a href=\"https://laohu8.com/S/META\">Facebook</a> and Instagram. \n</p>\n<p>\n     corporatefinancial-news \n</p>\n<p>\n     View source version on businesswire.com: https://www.businesswire.com/news/home/20250919662251/en/ \n</p>\n<pre style=\"white-space: pre\">\n \n    CONTACT:    Media Relations: \n</pre>\n<p>\n     media@bms.com \n</p>\n<p>\n     Investor Relations: \n</p>\n<p>\n     investor.relations@bms.com \n</p>\n<pre style=\"white-space: pre\">\n \n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  September 19, 2025 07:01 ET (11:01 GMT)\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0306807586.USD","symbol_name":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" (USD) INC QF","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2568874257","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2568874257","pubTimestamp":1758279660,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Bristol Myers Squibb  will announce results for the third quarter of 2025 on Thursday, October 30, 2025. Company executives will review financial results with the investment community during a conference call beginning at 8:00 a.m. ET.About Bristol Myers Squibb: Transforming Patients' Lives Through Science. At Bristol Myers Squibb, our mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. We are pursuing bold science to define what's possible for the future of medicine and the patients we serve. For more information, visit us at BMS.com and follow us on LinkedIn, X, YouTube, Facebook and Instagram.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0306807586.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" (USD) INC QF","LU0096364046.USD":"CT (LUX) I AMERICAN \"DU\" (USD) ACC","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","LU0267386448.USD":"FIDELITY FIRST ALL COUNTRY WORLD \"A\" (USD) INC","LU1261432733.SGD":"Fidelity World A-ACC-SGD","BMY":"施贵宝","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","LU0985481810.HKD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (HKD) INC M","BK4559":"巴菲特持仓","LU2125154935.USD":"ALLSPRING (LUX) WF GLOBAL EQUITY ENHANCED INCOME \"I\" (USD) INC","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","LU1074936037.SGD":"JPMorgan Funds - US Value A (acc) SGD","BK4588":"碎股","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU2242646821.SGD":"Fidelity Global Dividend Plus A-MINCOME(G)-SGD","LU1670710588.SGD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (SGD) ACC","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU0237698245.USD":"富达环球地产基金A","LU1868837300.USD":"CT (LUX) I AMERICAN FUND \"9\" (USD) ACC","LU2242652126.USD":"FIDELITY FUNDS GLOBAL DIVIDENDS PLUS \"A\" (USD) INC","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","LU1670710661.SGD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (SGD) INC","BK4007":"制药","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","IE00BFXG1179.USD":"BNY MELLON U.S. EQUITY INCOME \"B\" (USD) INC","LU1868836914.USD":"CT (LUX) I AMERICAN \"3\" (USD) ACC","BK4581":"高盛持仓","BK4532":"文艺复兴科技持仓","LU1670711123.USD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (USD) INC","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","LU1323610961.USD":"UBS (LUX) EQUITY SICAV - LONG TERM THEMES (USD) \"P\" (USD) ACC","LU1868837136.USD":"CT (LUX) I AMERICAN \"8\" (USD) ACC","LU0306806265.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" ACC","LU0225771236.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (USD) INC MF","BK4534":"瑞士信贷持仓","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU2360032135.SGD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (SGDHDG) INC","BK4585":"ETF&股票定投概念","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU1868836757.USD":"CT (LUX) I AMERICAN FUND \"2\" (USD) ACC","LU2125154778.USD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (USD) INC","LU0882574055.USD":"富达全球健康医疗A ACC","LU1032466523.USD":"高盛全球多资产收益组合Acc"},"translate_title":"新闻稿：百时美施贵宝将于2025年10月30日公布2025年第三季度业绩","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BMY":1.5},"content_text":"PRINCETON, N.J.--(BUSINESS WIRE)--September 19, 2025-- \n\n\n     Bristol Myers Squibb $(BMY)$ will announce results for the third quarter of 2025 on Thursday, October 30, 2025. Company executives will review financial results with the investment community during a conference call beginning at 8:00 a.m. ET. \n\n\n     Investors and the general public are invited to listen to a live webcast of the call at http://investor.bms.com. Materials related to the call will be available at http://investor.bms.com prior to the start of the conference call. \n\n\n     A replay of the webcast will be available at http://investor.bms.com approximately three hours after the conference call concludes. \n\n\n     About Bristol Myers Squibb: Transforming Patients' Lives Through Science \n\n\n     At Bristol Myers Squibb, our mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. We are pursuing bold science to define what's possible for the future of medicine and the patients we serve. For more information, visit us at BMS.com and follow us on LinkedIn, X, YouTube, Facebook and Instagram. \n\n\n     corporatefinancial-news \n\n\n     View source version on businesswire.com: https://www.businesswire.com/news/home/20250919662251/en/ \n\n\n \n    CONTACT:    Media Relations: \n\n\n     media@bms.com \n\n\n     Investor Relations: \n\n\n     investor.relations@bms.com \n\n\n \n \n\n\n  (END) Dow Jones Newswires\n\n\n  September 19, 2025 07:01 ET (11:01 GMT)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}